Kura Oncology, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $67.5M | $53.9M | $0 | — | — |
| Operating income | -$303.6M | -$193.2M | -$165.8M | -$139.9M | — |
| Operating expenses | $371.1M | $247.1M | $165.8M | $139.9M | $131.3M |
| Cash from operations | -$64.1M | $134.3M | -$124.8M | -$110.1M | -$104.6M |
| Capital expenditure | $6.6M | $472,000 | $168,000 | $626,000 | $1.1M |
| Free cash flow | -$70.7M | $133.8M | -$125.0M | -$110.7M | -$105.7M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $738.4M | $760.2M | $448.9M | $456.3M | $534.1M |
| Total liabilities | $564.2M | $346.5M | $51.7M | $36.0M | $27.4M |
Shares outstanding 88.8M · Free float 97.8%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.